| CAS NO: | 164204-38-0 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 588.48 |
|---|---|
| Formula | C23H34N3Na2O10P |
| CAS No. | 164204-38-0 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 100 mg/mL (169.9 mM) |
| Water: 100 mg/mL (169.9 mM) | |
| Ethanol: <1 mg/mL | |
| Other info | Chemical Name:
sodium
(oxido(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)phosphoryl)-L-leucyl-L-tryptophanate InChi Key: OQKHVXFOYFBMDJ-ODIUWQMJSA-L InChi Code: InChI=1S/C23H34N3O10P.2Na/c1-11(2)8-16(26-37(33,34)36-23-20(29)19(28)18(27)12(3)35-23)21(30)25-17(22(31)32)9-13-10-24-15-7-5-4-6-14(13)15;;/h4-7,10-12,16-20,23-24,27-29H,8-9H2,1-3H3,(H,25,30)(H,31,32)(H2,26,33,34);;/q;2*+1/p-2/t12-,16-,17-,18-,19+,20+,23-;;/m0../s1 SMILES Code: O[C@H]1[C@H](C)O[C@@H](OP(N[C@@H](CC(C)C)C(N[C@H](C(O[Na])=O)CC2=CNC3=CC=CC=C23)=O)(O[Na])=O)[C@H](O)[C@@H]1O |
| Synonyms | Phosphoramidon sodium |
| In Vitro | In vitro activity: Phosphoramidon is a powerful inhibitor of thermolysin without inhibiting the other endopeptidases such as trypsin, papain, chymotrypsin. Phosphoramidon reduces tumor cell invasion in CC531 cells. Cell Assay: In cultured endothelial cells, phosphoramidon inhibited the increase of ET-1 and C-terminal fragment (CTF) of big ET-1. However, phosphoramidon increased big ET-1 secretion |
|---|---|
| In Vivo | In rats bearing colon carcinoma CC531 xenografts, Phosphoramidon (250 mg/Rat i.p.) significantly reduces tumor cell growth. Intranasal phosphoramidon increases beta-amyloid levels in wild-type and NEP/NEP2-deficient mice, and thus can be use to model Alzheimer's disease (AD). |
| Animal model | WAG rats bearing colon carcinoma CC531 xenografts |
| Formulation & Dosage | Dissolved in 0.9% NaCl; 250 mg/Rat; i.p. injection |
| References | Biochem Biophys Res Commun. 1975 Jul 8;65(1):352-7; Surg Endosc. 2001 Aug;15(8):882-5; J Mol Neurosci. 2011 Mar;43(3):424-7. |
m.cnreagent.com